Blue Water Vaccines Presents New Data Supporting Universal Influenza Vaccine Candidate at the World Vaccine Congress 2022 in Washington, DC
21 April 2022 - 10:45PM
Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the
Company”), a biopharmaceutical company developing transformational
vaccines, today issued the below statement regarding its Form 8-K
filed with the Securities and Exchange Commission (“SEC”) on April
20, 2022, which included a presentation (the “WVC presentation”)
delivered by the Company at the World Vaccine Congress 2022 in
Washington, DC. This presentation by Brian Price, Ph.D., BWV’s Head
of Technology Strategy, shows identification of H3N2 and influenza
B epitopes of limited variability discovered by scientists at The
University of Oxford.
The Company previously presented data surrounding epitopes of
limited variability for H1 influenza strains, which are being used
to develop BWV-102, an H1 pre-pandemic vaccine. This latest data
included in the WVC presentation uses similar mathematical modeling
and research to find two epitopes of limited variability in H3N2
influenza and one epitope in influenza B. Provisional patents have
been recently filed for both H3 and influenza B antigens by the
Company’s licensors and will be used in combination with previously
identified H1 epitopes to form the basis for the Company’s
universal influenza vaccine candidate, BWV-101.
“The large seasonal burden of influenza warrants the development
of improved vaccines,” said Joseph Hernandez, Chief Executive
Officer of Blue Water Vaccines. “This data for H3N2 and influenza B
epitopes supports our commitment to develop a vaccine that provides
broad protection against all strains and eliminating the need for
annual immunization. We are excited to continue our collaboration
with The University of Oxford and move forward with this research
supporting one of our lead vaccine candidates.”
According to the World Health Organization, there are more than
1 billion influenza infections each year, 3 – 5 million of which
are considered severe, leading to between 290,000 – 600,000 related
respiratory deaths worldwide. Current influenza vaccines have
several shortcomings, including yearly reformulations 6 months
prior to influenza season leading to yearly administration and
typically provide protection to only 50% of the individuals that
receive the vaccine. Additionally, the CDC estimates about $87.1
billion USD is lost through absenteeism and healthcare costs in the
US and the WHO estimates around $4 billion US is spent on the flu
vaccine each year. Both the clinical toll of this disease and the
economic burden it poses warrants investigation and commitment to
the development of a universal influenza vaccine.
On April 20, 2022, BWV filed the BWV presentation on a Current
Report on Form 8-K with the Securities and Exchange Commission
(“SEC”) (“Current Report”). Please refer to the Current Report for
more details about the new data discussed therein. A copy of the
Current Report is available on the SEC’s website at
www.sec.gov.
About Blue Water Vaccines
Blue Water Vaccines Inc. is a biopharmaceutical company focused
on developing transformational vaccines to address significant
health challenges globally. Headquartered in Cincinnati, OH, the
company holds the rights to proprietary technology developed at the
University of Oxford, Cincinnati Children's Hospital Medical Center
(CCHMC), and St. Jude Children's Hospital. The company is
developing a universal flu vaccine that will provide protection
from all virulent strains in addition to licensing a novel
norovirus (NoV) S&P nanoparticle versatile virus-like particle
(VLP) vaccine platform from CCHMC to develop vaccines for multiple
infectious diseases, including norovirus/rotavirus and malaria,
among others. Additionally, Blue Water Vaccines is developing a
Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed
to specifically prevent the highly infectious middle ear
infections, known as Acute Otitis Media (AOM), in children. For
more information, visit www.bluewatervaccines.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as “anticipate,” “believe,” “forecast,”
“estimate,” “expect,” and “intend,” among others. These
forward-looking statements are based on BWV’s current expectations
and actual results could differ materially. There are a number of
factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. These factors
include, but are not limited to, risks related to the development
of BWV’s vaccine candidates, including, but not limited to BWV-301;
the failure to obtain FDA clearances or approvals and noncompliance
with FDA regulations; delays and uncertainties caused by the global
COVID-19 pandemic; risks related to the timing and progress of
clinical development of our product candidates; our need for
additional financing; uncertainties of patent protection and
litigation; uncertainties of government or third party payor
reimbursement; limited research and development efforts and
dependence upon third parties; and substantial competition. As with
any vaccine under development, there are significant risks in the
development, regulatory approval and commercialization of new
products. BWV does not undertake an obligation to update or revise
any forward-looking statement. Investors should read the risk
factors set forth in BWV’s Annual Report on Form 10-K for the
period ended December 31, 2021 and other reports filed with the SEC
on or after the date thereof. All of BWV’s forward-looking
statements are expressly qualified by all such risk factors and
other cautionary statements. The information set forth herein
speaks only as of the date thereof.
Contact Information:Media Relations513-620-4101Email:
media@bluewatervaccines.com
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Sep 2024 to Oct 2024
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Oct 2023 to Oct 2024